The purpose of this legislation is to modify how orphan drugs are treated under the Medicare Drug Price Negotiation Program. Orphan drugs are medications designed to treat rare diseases or conditions. This change aims to ensure that these drugs are included in price negotiations, which could make them more affordable for patients who need them. Key provisions of the legislation include adjustments to existing rules regarding the price negotiation process for orphan drugs. Specifically, it raises the revenue threshold for these drugs from $200 million to $400 million.